USask’s VIDO-InterVac receives $23M for COVID-19 vaccine research

April 30, 2020

The University of Saskatchewan’s Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) has been awarded $23M by the federal government to fast-track efforts to develop a COVID-19 vaccine. The funding will support pre-clinical testing and two phases of clinical trials. “This major federal investment will accelerate VIDO-InterVac’s efforts to develop a Canadian vaccine against COVID-19, critical work that will help protect the health and safety of all Canadians and people around the world,” said USask President Peter Stoicheff. USask (SK)